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Preamble
American College of Cardiology (ACC)/American Heart
Association (AHA) performance measure sets can serve as
vehicles to accelerate appropriate translation of scientiﬁc
evidence into clinical practice. These documents are
intended to provide practitioners and institutions that
deliver cardiovascular services with tools to measure the
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724quality of their care and identify opportunities for
improvement.
The present set of measures breaks important ground for
performance measurement. Here, the writing committee
was charged with developing measures to benchmark and
improve the quality of one of cardiology’s most common
and important procedures: percutaneous coronary inter-
vention (PCI). In this task, the ACC/AHA Task Force on
Performance Measures partnered with representatives from
several other organizations, including the Society for
Cardiovascular Angiography and Interventions (SCAI),
the American Medical Association (AMA)–Convened
Physician Consortium for Performance Improvement
(PCPI), and the National Committee for Quality Assur-
ance (NCQA). These bodies provided invaluable input in
the development and review of these measures.
The writing committee was instructed to follow the
methodology of performance measure development (1,2)
and to assure that the measures developed were aligned
with national standards so as to promote harmony across
measures. The writing committee was also charged with
constructing measures that maximally capture multiple
important aspects of quality (timeliness, safety, effec-
tiveness, efﬁciency, equity, and patient-centeredness)
while minimizing the reporting burden imposed on
participants.
As in other cases, all selected measures pose potential
challenges to implementation that could result in unin-
tended consequences. The manner in which these issues
are addressed is dependent on several factors, including the
measure design, data collection method, performance
attribution, baseline performance rates, reporting methods,
and incentives linked to these reports. These imple-
mentation challenges are appropriately discussed in indi-
vidual sections dedicated to each of the measures.
These new performance measures for PCI are notable
for several reasons. First, the writing committee considered
the key initial question of whether performing the proce-
dure was “appropriate,” in line with a growing body of
evidence in this area. Determining procedural appropri-
ateness of PCI is complex and requires comprehensive
documentation of the procedure’s priority, the presence
and severity of angina symptoms, the use of antianginal
medical therapies, and the presence and severity of stenosis
(as documented by angiography or other metrics of lesion
severity, e.g., intravascular ultrasound or fractional ﬂow
reserve). The present PCI performance measure set rep-
resents the ﬁrst time in the cardiology literature that a
speciﬁc performance measure has been constructed to
address procedural appropriateness.
Next, the writing committee listed important tasks to be
done by the care team before the procedure, including
determining whether the patient can and would be likely to
take dual-antiplatelet therapy on an ongoing basis (an
important requirement if drug-eluting stents are to be used),
as well as documenting the patient’s renal function (whichcan inﬂuence both the patient’s candidacy for the procedure
and procedural strategiesde.g., amount of iodinated
contrast). Many procedural and postprocedural factors that
can affect patient outcomes are considered in this measure
set, such as the use of embolic protection devices and the
documentation of ionized radiation and iodinated contrast
dosage. The writing committee also put the procedure in the
context of patients’ longitudinal disease process. Specif-
ically, they considered that procedural quality must extend
beyond the laboratory and should involve implementation
of appropriate secondary prevention cardiac rehabilitation
and medications to modify long-term risk. Finally, the
writing committee considered other indicators of quality
related to the interventionalist and the institution. These
measures include such factors as procedural volume and
whether the institution routinely tracks and benchmarks
their care relative to others in clinical registries.
Combined, these PCI metrics break important new
ground. As noted by the authors, the ﬁeld of quality
assessment and performance measurement in PCI is
maturing, and many advances are still needed. Neverthe-
less, this initial metric set provides a solid foundation for
quality improvement in the ﬁeld and sets the stage for
future advancement.
Eric D. Peterson, MD, MPH, FACC, FAHA
Chair, ACC/AHA Task Force on Performance Measures
1. Introduction
The ACC/AHA/SCAI/AMA-PCPI/NCQA Percuta-
neous Coronary Interventions Performance Measures
Writing Committee (the writing committee) was charged
with creating the ﬁrst performancemeasure set in this area. In
this measure set, the writing committee presents 11 mea-
sures, which are intended for ambulatory and hospital
(inpatient) settings. The measure set is summarized in
Table 1.
1.1. Scope of the Problem
The ACC/AHA/SCAI/AMA-PCPI/NCQA 2013 PCI
performance measurement set, which is available on the
PCPI Web site at http://www.ama-assn.org/apps/listserv/
x-check/qmeasure.cgi?submit¼PCPI, discusses in detail
the scope of the problem and opportunities for improving
the quality of care provided to patients undergoing PCI.
1.2. Structure and Membership of the
Writing Committee
The members of the writing committee included clinicians
specializing in interventional cardiology, general cardiol-
ogy, internal medicine, cardiac surgery, and cardiac reha-
bilitation, as well as individuals with expertise in guideline
development and performance measure development,
implementation, and testing. The writing committee
also included patient/consumer representatives and a payer
Table 1. 2013 ACC/AHA/SCAI/AMA-PCPI/NCQA Percutaneous Coronary Intervention Measurement Set
Measure Description*
1. Comprehensive Documentation of Indications for PCIy Percentage of patients aged 18 years for whom PCI is performed with comprehensive
documentation of the procedure. This documentation includes, at a minimum, the following
elements:
1. Priority (acute coronary syndrome, elective, urgent, emergency/salvage);
2. Presence and severity of angina symptoms (e.g., Canadian Cardiovascular Society
classification system);
3. Use of antianginal medical therapies within 2 weeks before the procedure, if any;
4. Presence, results, and timing of noninvasive stress test, fractional flow reserve, or
intravascular ultrasound, if performed; and
5. Significance of angiographic stenosis (may be quantitative or qualitative) on coronary
angiography for treated lesion.
2. Appropriate Indication for Elective PCIz Percentage of patients aged 18 years for whom elective PCI is performed in a native
coronary artery who have an appropriate indication for the procedure that suggests its overall
benefits outweigh its risks.
3. Assessment of Candidacy for Dual-Antiplatelet Therapyy Percentage of patients aged 18 years for whom PCI is performed who have documentation
in the medical record that an assessment of candidacy for initiation and duration of
dual-antiplatelet therapy was performed prior to the procedure.
4. Use of Embolic Protection Devices in the Treatment of
Saphenous Vein Bypass Graft Diseasez
Percentage of patients aged 18 years for whom saphenous vein graft PCI is performed who
received an embolic protection device during the procedure.
5. Documentation of Preprocedural Glomerular Filtration
Rate and Contrast Dose Used During the Procedurez
Percentage of patients aged 18 years for whom PCI is performed who have both
preprocedural estimated glomerular filtration rate or an indication that the patient is on
dialysis AND the administered contrast dose documented in the catheterization report or
procedure notes.
6. Radiation Dose Documentationz Percentage of patients aged 18 years for whom PCI is performed who have the
administered radiation dose documented in the catheterization report or procedure notes.
7. Postprocedural Optimal Medical Therapy Compositey Percentage of patients aged 18 years for whom PCI is performed who are prescribed
optimal medical therapy at discharge.
8. Cardiac Rehabilitation Patient Referraly Percentage of patients aged 18 years for whom PCI is performed who have been referred to
an outpatient cardiac rehabilitation / secondary prevention program.
9. Regional or National PCI Registry Participationy Participation in a national or multisystem geographic regional PCI registry that provides
regular performance reports based on benchmarked data.
10. Annual Operator PCI Volumez Average annual volume of PCIs performed by an operator over the previous 2 calendar years.
11. Annual Hospital PCI Volumey Annual volume of PCIs performed by a hospital over the previous calendar year.
*For comprehensive information on these measures, including measure exceptions, please refer to the complete ACC/AHA/AMA-PCPI/NCQA/SCAI performance
measurement specifications through the PCPI Web site (http://www.ama-assn.org/apps/listserv/x-check/qmeasure.cgi?submit¼PCPI).
yThese measures have been designated performance measures. Performance measures are process, structure, efficiency, or outcome measures that have been
developed with ACCF/AHA methodology, including the process of public comment and peer review, and have been specifically designated as performance measures by
the ACC/AHA Task Force on Performance Measures. These measures not only are intended for internal quality improvement but also may be considered for purposes
of public reporting or other forms of accountability.
zIndicated in shading, these measures have been designated quality metrics. Quality metrics are measures that have been developed to support self-assessment
and quality improvement at the provider, hospital, or healthcare system level. These metrics are valuable tools to aid clinicians and hospitals in improving quality of
care and enhancing patient outcomes but might not meet all specifications of formal performance measures and are, therefore, not appropriate for any use other than
internal quality improvement.
ACC indicates American College of Cardiology; AHA, American Heart Association; AMA-PCPI, American Medical Association–Physician Consortium for Performance
Improvement; NCQA,National Committee for Quality Assurance; PCI, percutaneous coronary intervention; and SCAI, Society for Cardiovascular Angiography and Interventions.
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725representative. The writing committee had representation
from the American Association of Cardiovascular and
Pulmonary Rehabilitation, Mended Hearts, SCAI, and the
Society for Thoracic Surgeons (STS).
1.3. Disclosure of Relationships With
Industry and Other Entities
The ACC/AHA Task Force on Performance Measures
makes every effort to avoid actual, potential, or perceived
conﬂicts of interest that could arise as a result of re-
lationships with industry or other entities (RWI). Detailedinformation on the ACC/AHA policy on RWI can be
found at http://www.cardiosource.org/Science-And-Quality/
Practice-Guidelines-and-Quality-Standards/Relationships-
With-Industry-Policy.aspx. All members of the writing
committee, as well as those selected to serve as peer re-
viewers of this document, were required to disclose all
current relationships and those existing within the 12
months before the initiation of this writing effort. ACC/
AHA policy also requires that the writing committee co-
chairs and at least 50% of the writing committee have no
relevant RWI.
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726Any writing committee member who develops new RWI
during his or her tenure on the writing committee is required
to notify staff in writing. These statements are reviewed
periodically by theTask Force and bymembers of thewriting
committee. Author and peer reviewer RWI relevant to the
document are included in the appendices: Please see
Appendix A for relevant writing committee RWI and
AppendixB for relevant peer reviewerRWI.Additionally, to
ensure complete transparency, the writing committee
members’ comprehensive disclosure information, including
RWI not relevant to the present document, is available on-
line at http://jaccjacc.cardiosource.com/DataSupp/ACCF/
2013_Comprehensive_RWI_WC.pdf. Disclosure infor-
mation for the Task Force is also available online at http://
www.cardiosource.org/ACC/About-ACC/Who-We-Are/
Leadership/Guidelines-and-Documents-Task-Forces.aspx.
The work of the writing committee was supported
exclusively by the ACC, the AHA, and the AMA, without
commercial support. Members of the writing committee
volunteered their time for this effort. Meetings of the
writing committee were conﬁdential and attended only by
committee members and staff from the ACC, AHA,
SCAI, AMA-PCPI, and NCQA.
2. Methodology
The development of performance measurement systems
involves identiﬁcation of a set of measures targeting a
speciﬁc patient population observed over a particular timeTable 2. 2013 ACC/AHA/SCAI/AMA-PCPI/NCQA Percutaneous Coronary
Dimensions of Care Measures Matrix*
Measure Name Diagnostics
1. Comprehensive Documentation of Indications for PCIy U
2. Appropriate Indication for Elective PCIz U
3. Assessment of Candidacy for Dual-Antiplatelet Therapyy U
4. Use of Embolic Protection Devices in the Treatment of
Saphenous Vein Bypass Graft Diseasez
5. Documentation of Preprocedural Glomerular Filtration Rate
and Contrast Dose Used During the Procedurez
U
6. Radiation Dose Documentationz
7. Postprocedural Optimal Medical Therapy Compositey
8. Cardiac Rehabilitation Patient Referraly
9. Regional or National PCI Registry Participationy
10. Annual Operator PCI Volumez
11. Annual Hospital PCI Volumey
*For comprehensive information on these measures, including measure exception
measurement set through the PCPI Web site (http://www.ama-assn.org/apps/listserv/
yThese measures are performance measures.
zIndicated in shading, these measures have been designated quality metrics an
appropriate for any other use (e.g., pay-for-performance, physician ranking, public re
ACC indicates American College of Cardiology; AHA, American Heart Association; AM
Improvement; NCQA, National Committee for Quality Assurance; PCI Percutaneous
Interventions.period. To achieve this goal, the ACC/AHA Task Force
on Performance Measures has outlined a set of mandatory
sequential steps (1). The following sections outline how
these steps were applied by the present writing committee.
2.1. Identifying Clinically Important Outcomes
To guide the selection of measures for inclusion in the
measure set, the writing committee sought to identify
structures, processes, and outcomes that are most mean-
ingful to patients undergoing PCI, as recommended by
recent guidelines and appropriate use criteria (AUC). A
key aspect was to determine outcomes that are most rele-
vant for patients. A complete list of the desirable outcomes
identiﬁed by the writing committee and how they relate to
the proposed process measures is included in the measure
speciﬁcations that can be found at http://www.ama-assn.
org/apps/listserv/x-check/qmeasure.cgi?submit¼PCPI.
2.2. Dimensions of Care
Given the multiple measurable domains of providing care,
the writing committee identiﬁed and explicitly articulated
the relevant dimensions of care that should be evaluated.
As part of the methodology, each potential performance
measure was categorized into its relevant dimension of care
(Table 2). Classiﬁcation into dimensions of care facilitated
identiﬁcation of areas in which evidence was lacking
and prevented duplication of measures within the set.
Diagnostics, patient education (including on the topics of
prognosis and etiology), treatment, self-management, andIntervention Performance Measure Set:
Patient Education Treatment Self-Management
Monitoring of
Disease Status
U
U U
U
U
U
U
U U U U
U
U
U
s, please refer to the complete ACC/AHA/AMA-PCPI/NCQA/SCAI performance
x-check/qmeasure.cgi?submit¼PCPI).
d are for use in internal quality-improvement programs only. They are not
porting programs).
A-PCPI, American Medical Association–Physician Consortium for Performance
Coronary Intervention; and SCAI, Society for Cardiovascular Angiography and
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727monitoring of disease status were selected as the relevant
dimensions of care for PCI performance measures.
In addition, to ensure the measure set would be as
comprehensive as possible, the writing committee evaluated
the potential measures against the Institute of Medicine
domains of healthcare quality (safety, effectiveness, patient-
centeredness, timeliness, efﬁciency, and equity) (3). The
writing committee focused primarily on processes of care,
but they also considered structural and outcome measures
for PCI. Although the writing committee cannot endorse
speciﬁc measures developed by others and believes that
many measures are needed to quantify the full spectrum of
relevant healthcare dimensions of quality, the measures
proposed in the present set are intended to complement
existing National Quality Forum–endorsed PCI measures.2.3. Literature Review
The practice guidelines and other clinical guidance docu-
ments that provided the basis for these measures can be
seen in Table 3.2.4. Deﬁnition and Selection of Measures
The writing committee reviewed both recent guidelines and
other clinical guidance documents, such as the “ACCF/
SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012
AppropriateUseCriteria forCoronaryRevascularization” (11).Table 3. Associated Guidelines and Other Clinical Guidance
Documents
ACCF/AHA/SCAI 2011 Guideline for Percutaneous Coronary Intervention (4)
ACCF/AHA 2013 Guideline for the Management of ST-Elevation Myocardial
Infarction (5)
ACC/AHA 2007 Guidelines for the Management of Patients with Unstable
Angina/Non–ST-Elevation Myocardial Infarction (6)
ACCF/AHA 2011 Focused Update of the Guidelines for the Management of
Patients with Unstable Angina/Non–ST-Elevation Myocardial Infarction
(updating the 2007 guideline) (7)
ACCF/AHA 2012 Focused Update of the Guideline for the Management of
Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction
(updating the 2007 guideline and replacing the 2011 focused update) (8)
AHA/ACCF 2011 Secondary Prevention and Risk Reduction Therapy for Patients
with Coronary and other Atherosclerotic Vascular Disease: 2011 Update (9)
ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary
Revascularization (10)
ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate Use Criteria for
Coronary Revascularization Focused Update (11)
ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012
Appropriate Use Criteria for Diagnostic Catheterization (12)
AATS indicates American Association for Thoracic Surgery; ACC, American
College of Cardiology; ACCF, American College of Cardiology Foundation; AHA,
American Heart Association; ASE, American Society of Echocardiography;
ASNC, American Society of Nuclear Cardiology; HFSA, Heart Failure Society of
America; HRS, Heart Rhythm Society; PCI, percutaneous coronary intervention;
SCAI, Society for Cardiovascular Angiography and Interventions; SCCM, Society
of Critical Care Medicine; SCCT, Society of Cardiovascular Computed To-
mography; SCMR, Society for Cardiovascular Magnetic Resonance; STEMI, ST-
elevation myocardial infarction; and STS, Society of Thoracic Surgeons.Thewriting committee also examined available information on
gaps in care and the clinical epidemiology of PCI.
All measures were designed to assess quality of care in pa-
tients undergoing PCI across a variety of ambulatory and hos-
pital settings to support achievement of the desirable outcomes
identiﬁed. The measures also were designed to allow for the
exclusion of patients with contraindications or other valid rea-
sons for exclusion from the measure. In deﬁning the measure
exceptions, the writing committee was guided by the AMA-
PCPI Recommendations for Speciﬁcation and Categoriza-
tion of Measure Exclusions (13), as discussed further below.
The writing committee evaluated the potential measures
against the ACC/AHA attributes of performance measures
(Table 4) to reach consensus on which measures should be
advanced for inclusion in the ﬁnal measure set; the Summary
Analysis Table (Appendix C) captures this evaluation process.
After the peer review and public comment period, the writing
committee reviewed and discussed the comments received,
and further reﬁnements were made in the measure set.
3. ACC/AHA/SCAI/AMA-PCPI/NCQA
2013 Percutaneous Coronary Intervention
Measures
3.1. Target Population and Care Period
The target population for the measures consists of all
patients undergoing PCI for coronary artery disease. That
said, a large focus of the writing committee was on
measures aimed at patients coming to the cardiac cath-
eterization laboratory for elective proceduresdthat is,
those originating as outpatients. Patients arriving from
the inpatient setting or emergency department and those
with acute coronary syndromes were considered second-
arily. The writing committee decided on this approach
for 2 reasons. First, in patients with acute coronary
syndromes, abundant data indicate that revascularization
with PCI is beneﬁcial, and prior measure sets focused on
this disease condition have included measures targeting
these patients (e.g., door-to-balloon time in ST-elevation
myocardial infarction). Second, in selected patients un-
dergoing elective procedures, such as those with chronic
stable angina, there is greater controversy as to the best
therapy that should be used. Patients referred to the
cardiac catheterization laboratory in these settings usually
have stable angina that is no longer controlled with
medications or have high-risk ﬁndings on a noninvasive
stress test. The beneﬁt of PCI in these patients is pri-
marily symptom reduction, and data on a mortality rate
beneﬁt for this group are limited (14–16).
3.2. Avoiding Overlap and Ensuring Alignment
With Existing Measure Sets and Guidelines
The writing committee made every effort to avoid overlap
with existing measure sets and to harmonize these
Table 4. ACC/AHA Task Force on Performance Measures: Attributes for Performance Measures
1. Evidence Based
High-impact area that is useful in
improving patient outcomes
a) For structural measures, the structure should be closely linked to a meaningful process of care that in turn is
linked to a meaningful patient outcome.
b) For process measures, the scientific basis for the measure should be well established, and the process should
be closely linked to a meaningful patient outcome.
c) For outcome measures, the outcome should be clinically meaningful. If appropriate, performance measures
based on outcomes should adjust for relevant clinical characteristics through the use of appropriate meth-
odology and high-quality data sources.
2. Measure Selection
Measure deﬁnition a) The patient group to whom the measure applies (denominator) and the patient group for whom conformance is
achieved (numerator) are clearly defined and clinically meaningful.
Measure exceptions and exclusions b) Exceptions and exclusions are supported by evidence.
Reliability c) The measure is reproducible across organizations and delivery settings.
Face validity d) The measure appears to assess what it is intended to.
Content validity e) The measure captures most meaningful aspects of care.
Construct validity f) The measure correlates well with other measures of the same aspect of care.
3. Measure Feasibility
Reasonable effort and cost* a) The data required for the measure can be obtained with reasonable effort and cost.
Reasonable time period b) The data required for the measure can be obtained within the period allowed for data collection.
4. Accountability
Actionable* a) Those held accountable can affect the care process or outcome.
Unintended consequences avoided b) The likelihood of negative unintended consequences with the measure is low.
ACC indicates American College of Cardiology; AHA, American Heart Association.
Adapted from: Normand SL, McNeil BJ, Peterson LE, et al. Eliciting expert opinion using the Delphi technique: identifying performance indicators for cardiovascular
disease. Int J Qual Health Care. 1998;10:247–60.
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728performance measures with other ACC/AHA/AMA-
PCPI performance measure sets when possible. For
example, the writing committee did not explore door-to-
balloon time as a performance measure, given that this
would overlap with performance measures for acute
myocardial infarction already constructed and endorsed by
numerous organizations. An example of harmonization
within the measure set is the postprocedural optimal
medical therapy composite measure in the present docu-
ment, which is aligned with the similar National Quality
Forum–endorsed ACCF facility-level measure.
4. General Discussion
4.1. Process Measures
Process measures have several advantages. They are more
readily under the control of clinicians than are structural or
outcome measures and also are actionable targets for
quality improvement. Performance measures of processes
are most useful when 1) they are directly linked to
improved clinical outcomes through robust evidence, and
2) true gaps in care exist. Expending resources to measure
processes that are already conducted at uniformly high
rates is not justiﬁed, particularly when burdensome chart
abstraction is required. An acknowledged limitation of
process measures is that they might not always indicate
how well the process was done. For example, measure 4
(use of embolic protection devices in the treatment ofsaphenous vein bypass graft disease) measures use of the
embolic protection device during PCI but does not capture
the technical skill with which it was deployed. We
considered including measures assessing technical care
processes performed in the cardiac catheterization labora-
tory but did not include any such measures because of the
lack of feasible, nonsubjective measurement criteria. This
should be an area of future investigation.
Two areas in which the writing committee tried to
advance process measures were in patient selection measures
and patient education/shared decision-making measures.
Given the novelty of these topics, these are discussed in
greater detail in the subsequent sections.
4.1.1. Patient Selection Measures
As with many procedures, evaluating patient selection and
determining appropriateness is a crucial ﬁrst step in
ensuring high-quality clinical care. Nevertheless, this has
not been done previously in performance measures for
procedures. Ideally, this evaluation would revolve around
both patients undergoing PCI and patients who are de-
ferred from the procedure, to ensure that underutilization
of potentially beneﬁcial treatments is not occurring (17).
Moreover, the indication (or reason) for the revasculariza-
tion is attributable to several providers, including the
referring physician and interventional cardiologist, as
well as their discussions with the consenting patient.
To date, the “ACCF/SCAI/STS/AATS/AHA/ASNC/
HFSA/SCCT 2012Appropriate Use Criteria for Coronary
Table 5. Preferred Attributes of Models Used for
Publicly Reported Outcomes
1. Clear and explicit definition of an appropriate patient sample
2. Clinical coherence of model variables
3. Sufficient high-quality and timely data
4. Designation of an appropriate reference time before which covariates
are derived and after which outcomes are derived
5. Use of an appropriate outcome and a standardized period of
outcome assessment
6. Application of an analytical approach that takes into account the
multilevel organization of data
7. Disclosure of the methods used to compare outcomes, including
disclosure of performance or risk-adjustment methodology in derivation
and validation samples
Reprinted with permission from Krumholz et al. (20).
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729Revascularization” (11) and the “ACCF/SCAI/AATS/
AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/
STS 2012 Appropriate Use Criteria for Diagnostic Catheter-
ization” (12) represent the professional societies’ attempt at
providing a framework for evaluating the appropriateness of
procedures in the cardiac catheterization laboratory (18). Prior
research demonstrated that the indication for revascularization
can be captured and evaluated for appropriateness, although
high rates of incomplete data collectionwere noted (19). These
criteria propose that emergency or urgent revascularization for
patients with acute coronary syndromes is generally considered
appropriate. However, for elective revascularization, several
important features should be considered in determining
appropriateness of cases, including symptom status, degree of
ischemia, anatomy, and current medical therapy. These ele-
ments are central to the data that should be captured as the
indication formost revascularizationprocedures.Therefore, the
initial goal of measure 1 (comprehensive documentation of
indications for PCI) and measure 2 (appropriate indication for
elective PCI) is to ensure that adequate information for
assessing the indication for revascularization procedures is
captured and reported, so that continued evaluation and feed-
back to improve both the AUC ratings and clinical care can
occur.
4.1.2. Patient Education/Shared Decision-Making
Measures
Although the aforementioned factors highlight the dif-
ﬁculty of determining when PCI is clinically indicated,
reaching a high-quality decision goes beyond meeting the
AUC. In an area in which decision making is so com-
plex, performance measurement ideally also would
address how the decision was made. This is necessary
because patient preferences can play an important role in
many cases, especially with regard to elective PCI. For
example, some patients whose medical history and
diagnostic testing results suggest PCI is indicated might
still want to consider other options. Conversely, there
will be patients for whom it is equivocal whether PCI is
indicated, but the patient nonetheless expresses a strong
preference to undergo PCI.
The ideal approach to decision making is to involve the
patient to the extent he or she wishes to be involved.
Performance measurement should reﬂect this process as
much as possible. Many patients will want to be involved
in these crucial decisions, and physicians’ performance
with these patients ideally would be assessed in part by
surveying patients about whether their input was solicited
and their preferences drove or at least inﬂuenced the
decision. Alternatively, some patients will prefer that their
physician make their decisions for them, and physicians
who do so in such instances should be regarded as giving
patient-centered care.
In addition, all patients should be educated about their
options. This education can be very brief in urgent settings,
such as when a patient is having an ST-elevationmyocardial infarction with cardiogenic shock. However, if
any uncertainty exists about the superiority of PCI versus
optimal medical therapy or surgical revascularization (as is
usually the case with elective PCI), then the patient should
be provided an opportunity to learn about the relative risks
and beneﬁts of therapies under consideration.
The writing committee struggled with whether to
include process measures that focused on decision making
and education through patient surveys. Surveys might be
able to address general quality of decisions and ask patients
about whether they were involved as much or as little as
they desired. Survey results could then be shared at the
physician and hospital levels, so both individual clinicians
and institutions could understand and improve their
decision-making processes. However, there are as yet no
validated instruments addressing these domains, nor have
other critical details been worked out. These limitations
left the writing committee less enthusiastic about sup-
porting a measure at the present time, but this should be a
priority area for future investigation.4.2. Outcome Measures
If the focus of process measures reﬂects the journey,
outcome measures shed light on the destinationdthe
end, rather than the means. Outcome measures offer the
potential advantage of providing readouts on entire
populations, rather than smaller population subsets, and
they focus on the “end results” of care that are most
important to clinicians and patients. The challenges with
outcome measures are primarily in the risk-adjustment
modeling methods, which, though never perfect, can
substantially enhance the ability to compare outcomes
across different delivery teams, settings, locations, and
systems (20). Krumholz et al. (20) have described 7
preferred attributes of models used for outcomes that are
publicly reported (Table 5), which this the writing com-
mittee strongly believes should remain at the core of any
performance measure that includes outcomes.
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7304.2.1. Level of Attribution/Aggregation
Contributions of multiple healthcare providers across mul-
tiple settings are reﬂected in outcomes associated with any
particular episode of care, and this can be especially true in
the case of PCI. In addition, various data sources and data
systems are the window into that episode, such that the
ability to aggregate data at the level of an individual clinician
versus a broader grouping (e.g., practice or hospital) will
depend on the types of data available and the outcomes being
evaluated. Although data are increasingly available, most
sources of information, like administrative claims data,
generally lack adequate granularity to be of meaningful use
for attribution of outcomes performance at the level of the
individual provider, which makes aggregation of PCI out-
comes more appropriate for the health system or hospital.
4.2.2. Infrequently Occurring Complications
Certain outcomes could be of inarguable importance in PCI
but occur rarely. Such outcomes are difﬁcult to interpret at
the individual-provider level simply because of the fact that
low-frequency events in a small sample size will produce
unreliable estimates of provider performance. For this
reason, certain measures are appropriately applied only to
larger aggregated provider groupings where sample sizes are
larger. These principles have substantial implications for
PCI outcomes because the rates of major complications,
such as death and the need for emergency coronary artery
bypass surgery, have decreased signiﬁcantly in recent years.
4.2.3. Death/Readmission
Death is perhaps the most important and least ambiguous
outcome measure. Proper risk adjustment isdand will
remainda mandatory cornerstone of mortality monitoring
for PCI. However, the writing committee also recognized
that even the best risk-adjustment model cannot correct for
potentially unmeasured confounders, and most risk-
adjustment models perform less well at the extremes of risk.
This requires a careful design of outcome measures to avoid
the unintended consequence of either penalizing facilities or
clinicians who take onmore difﬁcult cases or rewarding those
who avoid certain high-risk patients requiring treatment. In
this context, the writing committee did not believe it was
necessary to reproduce existing National Quality Forum–
endorsed measures that are already available in the public
realm on in-hospital and 30-day mortality rate after PCI.
The writing committee also considered a potential measure
of 30-day readmission after PCI, given reportedly high rates
of readmission and recent interest in this outcome by payers
and policymakers. As in the case of mortality rate, risk-
adjusted measures of 30-day readmission after PCI have
been developed, and we point interested readers toward
those measures (21–23).
4.2.4. Patient Surveys
Patient survey data have been used to compare the care
provided across health systems and providers. For example,the Mended Hearts pilot program conducted surveys of
patients 6 months after PCI, asking a range of questions:
“What type of procedure did you have?,” “Are you following
your medication regimen?,” and “What can be done to
improve knowledge of medications?” Medicare Health
Outcome Surveys also have been administered, as have a
NCQA-HCAHPS (Hospital Consumer Assessment of
Healthcare Providers and Systems) and system-level survey.
In addition, many individual hospital systems have devel-
oped and implemented diagnosis-related group-based
postdischarge surveys. Such surveys might be appropriate
for measuring certain outcomes, including subjective func-
tional status, symptoms, knowledge, and overall satisfaction
with the care process. However, critics point out that such
measures can be disproportionately weighted by items un-
related to care, including availability of channels on the
hospital television, food menu choices, and parking con-
venience. In addition, standardized tools for symptom
measurement and for patient subsets are generally lacking.
For example, the response to the question, “Did this pro-
cedure save your life?” could be different for a patient un-
dergoing PCI with an acute myocardial infarction and a
patient with stable angina. In addition, validated risk-
adjustment models for patient survey data do not
currently exist. Although the writing committee believes
that patient surveys are an important area for future
development (see also Section 4.1.2: Patient Education/
Shared Decision Making Measures), these limitations
raised concerns about their inclusion in the present
document.
4.3. Structural Measures
For PCI, measures to evaluate process and outcomes are
more clearly substantiated by an evidence base than are
structural measures. Still, compared with many clinically
important process and outcome measures, it is easier to
assess structural measures and, importantly, to track
changes longitudinally without need for risk adjustment.
Given these considerations, as well as interest in and evi-
dence on registries and the role of case volume in out-
comes, we elected to include 3 measures of structure:
measure 9 (regional or national PCI registry participation),
measure 10 (annual operator PCI volume) (quality
improvement only), and measure 11 (annual hospital PCI
volume). It is the consensus of the writing committee that
these structural measures can provide important contribu-
tions to the assessment of care equity and safety without
imposing undue data collection burden on hospitals or
practitioners. For both of the PCI case volume–speciﬁc
structural measures, existing standards encourage reporting
(24). However, although the experience of the operator and
the hospital performing PCI has been associated with
improved outcomes, it is not clear what speciﬁc threshold
volume of PCI cases represents a true clinically important
indicator. Thus, the intent of these case-volume measures
is to encourage data collection rather than speciﬁc targets.
JACC Vol. 63, No. 7, 2014 Nallamothu et al.
February 25, 2014:722–45 ACC/AHA/SCAI/AMA-PCPI/NCQA 2013 PCI Performance Measure
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challenges of accurately documenting operator volume
because some data systems cannot capture data for opera-
tors who work at multiple sites, and self-reporting can have
limitations. Given the challenges in capturing the required
data, the limitations of the evidence supporting a speciﬁc
threshold for operator volume, and the potential for un-
intended consequences, the writing committee designated
the operator volume metric for use only in internal quality
improvement because it does not comply with all the
desirable attributes required (see Table 4 and footnotes to
Table 1). The writing committee believes it is important to
encourage tracking of operator volume, but it would not be
appropriate to evaluate operators on the basis of volume of
procedures alone, so this measure should not be used in
accountability or public reporting programs.
5. Measures Included in This Set
5.1. Comprehensive Documentation
of Indications for PCI
Comprehensive documentation of the indication for PCI is
an absolute requirement for performing the procedure. This
should include an appropriate description of the key features
of the clinical presentation, along with documentation of
noninvasive stress testing and functional assessments (if
clinically indicated and performed) and the severity of
angiographic stenosis for the treated lesion. PCIs are per-
formed to improve symptoms or survival. Documentation of
these elements allows for an evaluation of the patient’s
indication for the procedure and also provides prognostic
utility. This ultimately permits an appropriate risk/beneﬁt
ratio to be inferred for the procedure. In addition, fulﬁllment
of this measure will enable assessment of other important
quality indicators derived from the ACC/AHA/SCAI
guideline for PCI (4) and the appropriate use criteria for
coronary revascularization documents (11,12). The docu-
mentation for many PCIs performed in the United States
lacks essential data to determine the procedure’s appropri-
ateness, making this a measure with a possibly important
gap in care (19). A potential concern is that several of the
features pertaining to the indication for PCI are attributable
to both the physician referring the patient for PCI and the
physician performing the procedure, which leads to chal-
lenges with attribution. Nonetheless, the writing commit-
tee’s opinion is that compiling all the required elements at
the level of the therapeutic intervention is a process of care
that is linked to desirable outcomes for patients undergoing
PCI. It is therefore the ultimate responsibility of the
physician performing the PCI and of the physician’s insti-
tution to accurately document key features.
5.2. Appropriate Indication for Elective PCI
There has been considerable discussion among the writing
committee members about this performance measure inthe context of the recently published AUC for coronary
revascularization (11), which include assessments of both
coronary artery bypass surgery and PCI, and the well-
documented variation (25) in practice of PCI across the
United States (11,12). Furthermore, prior attempts to
construct performance measures have not relied heavily on
AUC, so this represents one of the more innovative and
unexplored aspects of this performance measure set. The
writing committee therefore approached the creation of
this measure cautiously to maximize its value to users
without leading to unintended consequences that could be
harmful to patients.
Several key aspects of this measure deserve to be high-
lighted. To optimize our opportunity to improve care, we
focused on elective PCIs that occur in nonacute settings,
inasmuch as analyses of PCIs performed in acute settings
have shown that the vast majority of these procedures are
classiﬁed as appropriate according to AUC (19). In addi-
tion, even though we aimed to harmonize the document
with recently published guidelines and AUC, this perfor-
mance measure is not completely superimposable on their
deﬁnitions for 2 reasons. First, it is acknowledged that the
AUC cannot possibly include every conceivable patient
presentation of appropriateness. The AUC are created via a
modiﬁed Delphi approach, in which experts reach
consensus after being presented with speciﬁc clinical sce-
narios that focus on coronary anatomy, symptoms, current
medical therapy, and noninvasive studies. Thus, subtle
differences between the AUC and guidelines do exist,
particularly for PCI. For example, the guidelines for PCI
categorize the usefulness of these procedures for survival
beneﬁt in asymptomatic patients to be “uncertain in pa-
tients with 2- or 3-vessel [coronary artery disease] (with or
without involvement of the proximal [left anterior
descending] artery) or 1-vessel proximal [left anterior
descending] disease” (Class IIb recommendation), on the
basis of insufﬁcient data. However, the AUC, as rated by
experts, vary in their assessments of the usefulness of PCI
in this setting from uncertain to appropriate, on the basis
of the additional factors described previously (e.g., current
medical therapy, noninvasive studies). Second, the criteria
for the AUC are becoming a frequent part of daily clinical
practice and of quality-improvement efforts, but they are
not entirely noncontroversial (26). We therefore created a
measure that more broadly captured appropriate use of
PCI, using both the guidelines and the AUC as tools.
Finally, the writing committee considered that, at the
present time, the current measure does not entirely meet
the strict criteria for accountability measures as put forth by
Chassin et al. (27) and the ACC/AHA Task Force on
Performance Measures (28). For example, the measure-
ment of appropriateness of PCI is certainly consistent with
2 criteria, in that it is based on a strong foundation of
research and captures a process proximate to a desired
outcome (i.e., treating the right patient). Without existing
data on its use in test populations, however, it is difﬁcult to
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732know whether the current measure accurately captures
“appropriateness” (as opposed to encouraging gaming) or
whether it will lead to unintended consequences by
discouraging operators from taking on difﬁcult or high-risk
procedures where, although the risk is high, the beneﬁt
could be great (i.e., whether the measure will promote
underuse). Concern for this last issue is evident in the
evolving processes of the AUC, which have undergone
signiﬁcant changes since their early iterations (see below).
For these reasons, we designated this measure for internal
quality improvement only (see Appendix C for a summary
of the writing committee’s evaluation).
The writing committee also considered addressing the
inappropriate indications for elective PCI, as this has been
one of the most important features of the AUC. However,
the AUC documents speciﬁcally underscore the pivotal
role of clinical judgment in determining whether revascu-
larization is indicated for an individual patient. The rating
of a revascularization as inappropriate by any schematic
should not preclude a provider from performing PCI when
patient- and condition-speciﬁc data support that decision
(11,12). This is reﬂected in new language; “inappropriate”
has been changed to “rarely appropriate.” Nevertheless,
documentation of the reasons for performing a PCI should
still be mandatory. Because the criteria for appropriate
indications for elective PCI appear to be, in general, less
prone to various interpretations, the writing committee
decided to focus on appropriate procedures at the present
time. It is certainly possible that measurement of rarely
appropriate indications for elective PCI might become part
of future performance measures.
5.3. Assessment of Candidacy
for Dual-Antiplatelet Therapy
Dual-antiplatelet therapy is integral to preventing stent
thrombosis in patients treated with stents during PCI.
Current guidelines recommend dual-antiplatelet therapy
for 4 weeks in patients who are treated with bare metal
stents and 1 year in patients who are treated with a drug-
eluting stent, though it is recognized that this recom-
mendation is in ﬂux (4). In any case, considerable data
suggest that premature cessation of dual-antiplatelet ther-
apy is associated with an increased risk of stent thrombosis
and resultant myocardial infarction or death (29,30). It is
therefore important that an assessment of tolerability of
and adherence with long-term dual-antiplatelet therapy be
made before the procedure and that the importance of
dual-antiplatelet therapy be discussed with the patient
before and after the procedure. For example, this might
include (but not be limited to) questions about scheduled
or anticipated surgeries. Ideally, this discussion should be
part of the informed consent process, and the intended
duration of dual-antiplatelet therapy should be docu-
mented clearly before the procedure. It is recognized that
ascertainment of candidacy for dual-antiplatelet therapy
might not be feasible during emergencies or when a patientis unresponsive, and these patients have been excluded
from the measure.
5.4. Use of Embolic Protection Devices
in the Treatment of Saphenous Vein Bypass
Graft Disease
It is the opinion of the writing committee that, when
technically feasible, embolic protection devices should be
used during saphenous vein graft PCIs. This is consistent
with current (2011) ACCF/AHA/SCAI guidelines, which
made embolic protection device use during saphenous vein
graft intervention a Class I recommendation (4). Of
course, the writing committee recognizes that it might not
be technically feasible to use an embolic protection device
in all cases, depending on such factors as vessel tortuosity,
lesion location and severity, vessel size, and Thrombolysis
in Myocardial Infarction (TIMI) ﬂow. If an embolic pro-
tection device is not used during saphenous vein graft PCI,
the writing committee believes that documentation of
technical reasons, unsuitable anatomy, or patient refusal of
the device should be provided. This measure was desig-
nated for internal quality improvement only because a
potential unintended consequence of this measure could be
that it might inappropriately encourage use of embolic
protection devices by operators without sufﬁcient experi-
ence in their use.
5.5. Documentation of Preprocedural
Glomerular Filtration Rate and Contrast Dose
Used During the Procedure
Assessment of renal function should be a standard part of
the preprocedural work-up of patients undergoing coronary
angiography and intervention. It is well recognized that
serum creatinine concentration by itself is a poor surrogate
for renal function and that estimated glomerular ﬁltration
rate (GFR) should be calculated for each patient (4). Renal
function (as estimated by calculated GFR) is important for
dosing medications (including anticoagulants) and contrast
media. An excess of bleeding events has been reported in
patients who do not receive appropriately adjusted dosing
of anticoagulation in the setting of renal dysfunction
(31,32). Furthermore, current guidelines recommend use
of preprocedural hydration in patients who have a reduced
GFR (33,34). Estimated GFR should be calculated as
close to the day of the procedure as possible and should be
documented in the medical record, ideally as part of the
preprocedural checklist.
The writing committee also recommends that the total
amount of contrast volume administered to a patient
should be documented clearly in the procedure report. The
risk of contrast-induced renal injury increases with
increasing volume of contrast administered, and physicians
should follow a principal of “as low as reasonably pos-
sible,” especially in patients who have preexisting renal
dysfunction (35). Although recent studies suggested an as-
sociation between high total contrast dose (or GFR-based
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do not believe that the current evidence is robust enough to
support a speciﬁc contrast threshold that should not be
exceeded under any circumstance (4,32). In addition, no
evidence indicates that simply documenting the dose is
linked to improved patient outcomes. For these reasons, the
writing committee designated this measure only for internal
quality improvement at the present time. Of course, indi-
vidual circumstances during a case often will dictate whether
the use of additional contrast is worthwhile for the safety of
the procedure. Nevertheless, recording the total volume of
contrast used for each case, as required by the measure,
should serve as the ﬁrst step toward understanding and
modifying patterns of contrast use in cardiac catheterization
laboratories.
5.6. Radiation Dose Documentation
Current guidelines recommend that procedural radiation
dose should be recorded for all patients and should be
limited to “as low as reasonably achievable,” according to
clinical circumstances. Measures of radiation dose include
total air kerma at the interventional reference point, air
kerma area product, ﬂuoroscopy time, and number of cine
images (4). Furthermore, it is recommended that every
catheterization laboratory deﬁne thresholds, with corre-
sponding follow-up protocols, for patients who receive a
high procedural radiation dose. It is most typical to report
total ﬂuoroscopy time, but the writing committee recog-
nized that this is a limited measure of total radiation
exposure and dose. All contemporary interventional x-ray
systems report the total air kerma area product (in Gray
[Gy]) and air kerma area product (in Gycm2). When
available, one or both of these measures should be docu-
mented in the procedure report in addition to ﬂuoroscopy
time. At the present time, the writing committee desig-
nated this measure for internal quality improvement only
to avoid potential unintended consequences, such as op-
erators feeling a need to limit additional imaging even
when it would be clinically useful (see Appendix C for a
summary of the analysis).
5.7. Postprocedural Optimal Medical Therapy
Composite
Medical therapy, including aspirin, P2Y12 inhibitors, and
statins, has been proved to reduce all-cause mortality and
cardiovascular morbidity in multiple studies. These medi-
cations should be prescribed to all patients who are eligible
for them after PCI, except for the rare circumstances in
which the life expectancy of the patient is limited or the
patient has a known allergy or intolerance. Despite the
strong endorsement from the guidelines and their robust
evidence base, the use of these medications is less than
optimal, particularly for statin therapy. Recently, Borden
and colleagues (36) evaluated the use of optimal medical
therapy in patients undergoing PCI for stable disease who
were enrolled in the National Cardiovascular Data RegistryCathPCI Registry. Statins were prescribed to 83% of pa-
tients who were discharged alive after PCI, after exclusion
of patients with a contraindication to or history of intol-
erance of statins. Thus, opportunity remains for substantial
improvement in the use of these medications in patients
undergoing PCI (36). Incorporating these medications
into the standard post-PCI order sets and having a detailed
discussion of their beneﬁts can be very effective at ensuring
patient adherence, particularly with statin therapy (37).
This measure harmonizes closely with the corresponding
facility-level postprocedural optimal medical therapy
composite measure from the ACC (38).
5.8. Cardiac Rehabilitation Patient Referral
Cardiac rehabilitation is a multidisciplinary exercise-based
outpatient service that has been proved to provide patient
beneﬁt in terms of improved functional status, quality of
life, medical resource use, and, ultimately, mortality rate
reduction (39–46). Patients with coronary artery disease
treated with PCI are at high risk of recurrent events and are
particularly suitable for risk reduction via cardiac rehabili-
tation. Unfortunately, cardiac rehabilitation is a vastly
underutilized service, with available data indicating that
less than half of eligible patients ultimately enroll in a
program (47). There are numerous barriers to referral,
entry, and completion of cardiac rehabilitation by patients.
Although some of these barriers are ﬁnancial or system
related (e.g., lack of a geographically convenient program),
physician referral is a modiﬁable barrier. Explicit physician
referral of patients to cardiac rehabilitation has been shown
to substantially increase the likelihood of patient enroll-
ment (47,48). Although it could be argued that referral is
the responsibility of a patient’s primary physician or other
members of the healthcare team, the writing committee
believes that cardiac rehabilitation referral should be part of
the comprehensive care of a patient undergoing PCI and
should be the responsibility of the providers involved with
that procedure, in a manner similar to treatment of dysli-
pidemia. Referral during the index hospitalization for PCI
is therefore optimal. The performance measure takes into
account appropriate exclusions, such as medical non-
suitability (e.g., history of comorbidities), patient prefer-
ence, and lack of availability of a suitable program. This
performance measure harmonizes closely with the corre-
sponding measure from the ACCF/AHA/PCPI coronary
artery disease performance measure set. In the future,
broadening this measure to assess levels of participation on
the basis of attendance, rather than simply referral, might
be examined.
5.9. Regional or National PCI Registry
Participation
The writing committee believed strongly that every cath-
eterization laboratory should participate in a national or
regional PCI registry for benchmarking purposes. The
beneﬁts of participating in a registry include the ability to
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those of similar laboratories of comparable volumes, so that
the laboratory staff understands their outcomes in relation
to national or regional standards. We believe this measure
will encourage more cardiac catheterization laboratories to
participate in large multicenter databases and collaboratives
to improve the evidence base to support quality efforts in
PCI.
5.10. Annual Operator and Hospital PCI Volume
The writing committee designated the operator procedure
volume as appropriate for internal quality improvement
only, as indicated in Appendix C. It is well recognized that
operator volume, though useful, is a limited surrogate for
quality. This is due partly to the difﬁculty of collecting
volume data for individual operators, who can practice
across numerous facilities and even states. The volume of
the catheterization laboratory in which an operator works
seems to be a more trustworthy surrogate for quality than
does individual operator volume. Although updated rec-
ommendations exist for operator and institutional volumes
(24), they are still based on observational studies that
looked at a variety of facility volume thresholds. However,
the preponderance of evidence suggests that facilities that
perform <200 PCIs per year have worse outcomes than
facilities that perform more procedures. Given the limita-
tions of the evidence base, the writing committee felt
strongly that no speciﬁc threshold should be required for
these measures, though it did see value in collecting these
data for institutional and operator quality assurance. The
writing committee also recognized the potential challenges
of operators who are recently out of training or who
transiently cease performing procedures because of job
changes or health reasons (e.g., pregnancy). A potential
unintended consequence of this measure that was discussed
by the writing committee is that an operator might perform
unnecessary procedures to achieve a threshold level. Future
iterations of this measure will need to also address whether
adjunctive coronary procedures (e.g., fractional ﬂow
reserve, intravascular ultrasound) and noncoronary pro-
cedures (e.g., transcatheter aortic valve replacement) should
be included in these assessments of operator and institu-
tional volume, given that these techniques require over-
lapping technical skills.
6. Potential Measures Considered
But Not Included in This Set
6.1. Process Measures
The writing committee considered several additional pro-
cess measures for inclusion. A longitudinal measure
assessing use of dual-antiplatelet therapy at 30 days and 1
year was considered. Although such a measure has a greater
likelihood of improving care, the logistical challenges ofcollecting longitudinal drug data on an outpatient basis
made it difﬁcult to implement this measure at the present
time. We are hopeful that advances in information tech-
nology, electronic health records, and outpatient registries
will make reliably collecting these data possible in the
future.
We also examined additional measures related to ad hoc
PCI (PCI performed during the same session as diagnostic
angiogram) and multivessel PCI. These measures focused
on examining the core question of whether the PCI was
appropriate in the context of additional therapeutic op-
tions, like medical therapy and coronary artery bypass
surgery. This was an area of great interest and much dis-
cussion for the writing committee. However, in the end the
group felt limited in our ability to construct feasible mea-
sures that could be applied reliably in clinical practice. We
decided that these topics were ultimately beyond the
charge of a writing committee focused on PCI. Our
greatest barriers were the lack of deﬁnitive data on the risks
and beneﬁts of ad hoc PCI and multivessel PCI and their
role in shared decision making by patients and providers
(49,50). The writing committee, therefore, decided that
this topic might be considered in future updates of these
measures or might be better handled by a writing com-
mittee focused entirely on developing performance mea-
sures for coronary revascularization (rather than just PCI).
6.2. Outcome Measures
As noted previously, outcome measures are highly desirable
but often difﬁcult to incorporate into performance measure
sets because of vulnerability to inﬂuences outside the pro-
vider’s control. Thus, outcome measures, particularly those
intended for use in accountability, should be supported by
strong data and should address risk-adjustment concerns.
For example, the writing committee considered a measure
of the incidence of dialysis after PCI. However, this was
ultimately not included because the need for unexpected
dialysis after PCI is extremely rare, and when dialysis does
occur after PCI, it is often in patients with marginal renal
function before the PCI for whom the possibility of dialysis
was discussed previously. Creating a measure in this area
might dissuade these patients, who are often at high risk for
coronary artery disease, from undergoing PCI. Several
members of the writing committee supported the inclusion
of a related measure of acute kidney injury after PCI that
would depend on laboratory assessments of renal function.
However, controversy exists about the diagnosis of acute
kidney injury in this setting, and in many patients, it would
require multiple blood tests that are otherwise not indicated.
Similarly, the writing committee considered a measure
assessing rates of blood transfusion after PCI. This was not
included as a measure because the writing committee felt
that it is currently challenging to adequately account for all
the factors related to the decision to transfuse patients after
PCI, some of which might be related only indirectly to the
procedure. Emergency coronary artery bypass surgery after
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widespread use of stents, the incidence is extremely small,
which would make it an unreliable measure. Finally, a
measure of periprocedural infarction based on cardiac
biomarkers after PCI was considered. However, stan-
dardized collection of cardiac biomarkers after PCI is still a
variable practice, and this strongly inﬂuences rates of peri-
procedural infarction. Given these concerns and that stan-
dardized collection of cardiac biomarkers after PCI is not a
Class I recommendation in recent PCI guidelines, this
measure was not included.
Three outcome measures, in particular, were considered
strongly by the writing committee, and these are reviewed
in detail in the following sections.
6.2.1. Angina
The writing committee considered a measure of assess-
ment of angina. Given that one of the primary reasons for
performing PCI is to reduce angina, the concept of
assessing anginal class in a structured way before PCI, and
reassessing it in the same way after PCI, has intuitive ap-
peal. However, the writing committee noted several chal-
lenges. First, it was recognized that angina/ischemia can
present in different ways, and there was little agreement on
how to account for unusual symptoms presenting as an
“anginal equivalent.” Second, it was recognized that
rigorous, standardized anginal class assessment (e.g., the
Seattle Angina Questionnaire), though standard in clinical
trials, is not typically performed in the clinical setting, and
that more common systems, like the Canadian Classiﬁ-
cation System, have poor reliability and are too subjective.
These issues created a tension between the feasibility of a
measure related to angina assessment and its usefulness.
For these reasons, the writing committee decided not to
include an assessment of angina in the present set, but it
believes this should be an area of future development.
6.2.2. Thirty-Day Mortality Rate
The writing committee considered a mortality measure, and
the 30-day endpoint was discussed in particular, because
this was identiﬁed as the time point (as opposed to 1 year) at
which outcomes would be most closely related to the index
procedure. For the reasons discussed in Section 4.2, death as
an outcome measure has obvious appeal. It is overall an
unambiguous and unarguable endpoint and, along with
stroke, is generally considered one of the worst possible
outcomes of a PCI procedure. The challenges to using
30-day mortality rate as a performance measure relate pri-
marily to risk-adjustment issues, and 2 main sentiments
prevailed: 1) There was a strong desire to avoid penalizing
operators for taking difﬁcult cases. This arose from recog-
nition that risk adjustment is less robust at the extremes of
risk, as well as from acknowledgment of some of the un-
intended negative consequences that could result from
focus on this outcome, at the individual-operator level, in
terms of avoidance of difﬁcult cases altogether or anundesirable displacement of them to nearby regions and
operators subject to lesser scrutiny. 2) It was recognized that
mortality rate has been a component of numerous prior
efforts, and there was a desire to avoid duplicative efforts.
For these reasons, the writing committee opted not to
include a measure related to 30-day mortality rate.
6.2.3. Revascularization
The occurrence of a negative outcome after PCI, such as
restenosis or stent thrombosis, was also considered as an
outcome measure. The writing committee generally agreed
that restenosis and stent thrombosis are negative outcomes
but was not in agreement that all of the factors that
contribute to these outcomes are understood, or at least
there was some lack of consensus about the extent to which
these outcomes are related to factors within the operator’s
direct control. More importantly, restenosis and stent
thrombosis are both now relatively low-frequency events
for any individual operator. In addition, presentation with
either restenosis or thrombosis is not always to the same
medical center where the index procedure was performed,
which creates a challenge to accurately ascertaining the
incidence of these outcomes at the individual-operator or
center level. For these reasons, the writing committee did
not include any outcome measures related to restenosis or
thrombosis.
6.3. Structural Measures
Two additional structural measures related to use of
standardized protocols were carefully considered by the
writing committee. However, these structural measures
were determined to be inappropriate for inclusion in the
measure set at the present time. In both cases, use of
protocols has been advocated as a way to potentially
mitigate risk for patients in developing complications from
PCI.
First, given the high potential for morbidity and mor-
tality associated with use of antiplatelet and anticoagulation
therapy, the writing committee considered a measure to
assess use of a standardized protocol for these agents.
However, despite their extensive use of these protocols,
there is scant evidence to link their use of a protocol to
improved patient outcomes. Dosing guidelines exist for
speciﬁc agents; however, there is a wide range of variability
even in the guidelines to account for important clinical
considerations, including adjustments for renal impair-
ment, concomitant warfarin anticoagulation, and other
clinical factors. Thus, the writing committee decided that
the proposed measure offered little added value to quality
care assessment at the present time, given the complexity
required for its effective implementation. The writing
committee does encourage development and implementa-
tion of protocols for antiplatelet and anticoagulant therapy
as appropriate on a local basis, and reconsideration of this
measure might occur in future iterations of this measure set
as the evidence base evolves.
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protocol for managing contrast-related nephropathy before
and during PCI but decided that the evidence base is not
substantive enough to support inclusion of such a measure
at the present time. However, as discussed in Section 5.1,
the writing committee did elect to include documentation
of preprocedural estimated GFR and contrast dose as in-
ternal quality-improvement measures in this set. There is a
tight linkage between GFR and contrast dose and devel-
opment of contrast-related nephropathy. The writing
committee felt that these measures should capture, with
sufﬁcient granularity, important data to guide local
improvement efforts. As the evidence base to guide the
management of contrast-related nephropathy continues to
evolve, consideration for inclusion might be appropriate in
future iterations of this measure set.
7. Areas for Further Research
The writing committee identiﬁed 4 areas of interest for
further investigation. Although the areas are relevant to
performance measures in general, the writing committee
felt they would have particularly important implications for
measurement with regard to PCI. Some of these have been
discussed throughout the present document in relevant
sections but are highlighted here for additional emphasis.
7.1. Documentation of Prescription of
Drugs Versus Filling of Drug Prescriptions
and Optimal Dosing of Drugs
The writing committee felt that it will be important in
future work to examine moving beyond documentation of
only the prescription of drugs to the actual ﬁlling of drug
prescriptions and the optimal dosing of drugs. Unfortu-
nately, using existing data collection systems to measure
these is currently too difﬁcult, expensive, and prone to error
to serve as a useful quality measure. Additionally, a patient
could be seen by several practitioners who have different
standards for optimal dosing.
7.2. Limitations of Current Data Systems for PCI
Administrative claims data are used for a large number of
analyses focused on PCI utilization. Although valuable for
capturing use and costs, these data are inadequate as a
source for quality measures. For example, the Dartmouth
Atlas has suggested for several years that substantial
regional differences exist in PCI utilization, leading to
concerns that PCI is overutilized (25). A thorough un-
derstanding of the reasons for regional variation in these
procedures and their value for outcomes, such as im-
provements in angina and quality of life, however, is still
lacking. In addition, hospital-based systems for collecting
data on PCI are increasingly incomplete because most
elective procedures are now done with an outpatient or
observational status rather than an inpatient status.7.3. Shared Accountability
Most patients who have undergone a PCI have come into
contact with more than one physician before receiving their
procedure from an interventional cardiologist. These can
include a primary care physician, emergency physician,
hospitalist, intensivist, noninvasive cardiologist, and clin-
ical cardiologist. Accountability for quality needs to occur
throughout the process and should be shared by all the
providers who care for the patient. Although accountability
and subsequent outcomes lie primarily with the interven-
tionist, many steps in the process that occurred before the
PCI can contribute to optimizing patient care. This is
equally true for care that happens after the PCI.
7.4. Patient Surveys
The writing committee suggests that hospitals survey their
PCI patients about their level of knowledge, level of edu-
cation, and perception of outcomes of their procedures.
This is an exciting and important method of ascertaining
and ensuring patient education with regard to their
perceived outcomes of PCI. The writing committee did
not support including this as a measure because the out-
comes of PCI vary according to presenting symptoms; for
example, patients with an acute myocardial infarction could
have an improved risk of mortality as a result of their PCI,
but patients undergoing elective PCI for chronic stable
angina probably have no improvement in their outcome
other than symptom relief.
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744Appendix C. ACC/AHA/SCAI/AMA-PCPI/NCQA 2013 Percutaneous Coronary Interventions
Performance Measures: Summary Analysis TableCompletely
Fulﬁlls Attribute*
Partially Fulﬁlls or
Does Not Fulﬁll
Attribute* Summary Commentsx
Measures included in the performance measure set
Comprehensive Documentation of PCIy 1,2,3,4
Appropriate Indication for Elective PCIz 1,2,3b,4 3a Lack of existing data on use in test populations makes it difﬁcult
to know whether the current measure accurately captures
“appropriateness” (as opposed to encouraging gaming) or
whether it will lead to unintended consequences by punishing
providers.
Assessment of Candidacy for Dual-Antiplatelet Therapyy 1,2,4 3 ACCF National Cardiovascular Data Registry CathPCI Registry is
unable to measure this. It will require additional chart
documentation and abstraction.
Use of Embolic Protection Devices in the Treatment of
Saphenous Vein Bypass Graft Diseasez
2,3b,4 1b, 3a The guideline Class of Recommendation is 1, and Level of
Evidence is only B.
Documentation of Preprocedural Glomerular Filtration Rate
and Contrast Dose Used During the Procedurez
2,3,4 1 There are few potential unintended consequences, given that
there are no thresholds speciﬁed in this measure. However,
evidence indicates that doses are inconsistently documented.
Therefore, although this measure is expected to have limited
impact because it requires only documentation, it is an
intermediate step to a more meaningful performance
measure.
Radiation Dose Documentedz 2,3,4 1 There are few potential unintended consequences given that
there are no thresholds speciﬁed in this measure. However,
evidence indicates that doses are inconsistently documented.
Therefore, although this measure is expected to have limited
impact because it requires only documentation, it is an
intermediate step to a more meaningful performance
measure.
Postprocedural Optimal Medical Therapy Compositey 1,2,3,4 Registry data are currently limited, making it unfeasible to
capture speciﬁc medical, patient, or system exceptions.
Cardiac Rehabilitation Patient Referraly 1,2,3,4
Regional or National PCI Registry Participationy 2,3,4 1 The guideline Class of Recommendation is 1, but Level of
Evidence is only C.
Annual Operator PCI Volumez 2,3b 1,3a,4  There are potential unintended consequences because opera-
tors might be more inclined to intervene when the procedure is
not indicated.
 This measure could pose a feasibility challenge if a person
works at multiple sites.
Annual Hospital PCI Volumey 2,3 1,4 Smaller hospitals might be more inclined to intervene when the
procedure is not indicated, to achieve higher volumes.
Measures considered but not included in the performance measure set
Assessment of patient knowledge of beneﬁts and risks of PCI 1,4b 2,3,4a  Limited availability of validated surveys.
 Limited existing literature on patient education or actionable
methods to improve it.
Postprocedural dialysis 1 2,3,4  Dialysis might not be related to PCI.
 Long measurement period is needed to capture data, given it is
a rare event.
Postprocedural blood transfusion 1 3,4 Bleeding might occur outside interventionalists’ locus of control.
Measurement of cardiac biomarkers N/A 1,2,3,4 Evidence is still controversial.
Periprocedural angina assessment 1,2 3,4 This is a potentially high-impact area with validated instruments,
yet little data exist on how to best incorporate validated
instruments into routine practice without excessive effort or
costs.
Aspirin/thienopyridine at discharge 3,4 1,2 There is little room for major impact or improvement, given
existing evidence of already high compliance rates.
*Corresponding numbers and letters are linked to the ACC/AHA Task Force on Performance Measures Attributes for Performance Measures. Numbers indicate the
entire attribute, and letters indicate specific attribute subcriteria.
yThese measures are performance measures.
zIndicated in shading, these measures have been designated quality metrics. Quality metric are designated for use in internal quality-improvement programs only.
These measures are not appropriate for any other purpose (e.g., pay-for-performance, physician ranking, or public reporting programs).
xWhere applicable, the writing committee provided summary comments about why certain measures were included or not included in the final measure set. For all
attributes noted as “partially or does not fulfill attribute,” the writing committee provided summary comments.
ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; GFR, glomerular filtration rate; and PCI, percutaneous coronary
intervention.
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745Attributes and subcriteria key:1. Evidence based:
1a. For structural measures, the structure should be
closely linked to ameaningful process of care that
in turn is linked to ameaningful patient outcome.
1b. For process measures, the scientiﬁc basis for the
measure is well established, and the process
should be closely linked to a meaningful patient
outcome.
1c. For outcome measures, the outcome should be
clinically meaningful. If appropriate, perfor-
mance measures based on outcomes should
adjust for relevant clinical characteristics
through the use of appropriate methodology
and high-quality data sources.
2. Measure selection:
2a. The patient group to whom the measure applies
(denominator) and the patient group for whom
conformance is achieved (numerator) are clearly
deﬁned and clinically meaningful.
2b. Exceptions and exclusions are supported by
evidence.2c. The measure is reproducible across organiza-
tions and delivery settings.
2d. Face validitydThe measure appears to assess
what it is intended to.
2e. Content validitydThe measure captures most
meaningful aspects of care.
2f. Construct validitydThe measure correlates
well with other measures of the same aspect of
care.
3. Measure feasibility:
3a. The data required for the measure can be ob-
tained with reasonable effort and cost.
3b. The data required for the measure can be ob-
tained within the period allowed for data
collection.
4. Accountability:
4a. ActionabledThose held accountable can affect
the care process or outcome.
4b. The likelihood of negative unintended conse-
quences with the measure is low.
